# data[].attributes.attachment_link.provider_name
Ingeniero Químico Emprendedor: Ingeniería Industrial rama Química

# data[].attributes.attachment_link.readable_text
Al convertir la energía eólica y solar en combustible, la energía-a-X puede liberar el transporte, la calefacción y los procesos industriales de los combustibles fósiles, una vez que los precios caigan.

En todo el mundo se está generando más y más electricidad a partir de la energía eólica y solar. La tecnología ha avanzado enormemente en las últimas décadas y, por lo tanto, el valor de la energía renovable es que la vida del otoño.

Pero si miramos al otro lado del sector de la electricidad en nuestro consumo total de energía, las energías renovables siguen siendo sólo una muestra. La calefacción, el transporte y los procesos industriales siguen estando dominados por los combustibles fósiles, y muchos de esos sistemas no pueden funcionar con electricidad; tienen combustible.

Ahí es donde entra en juego la energía-a-X (también llamada P2X o PtX). Un término general, cubre muchos procesos que convierten la electricidad en calor, elementos o combustibles artificiales, lo que implica que asociar el aumento de una parte de nuestro sistema de energía puede dar un buen día al carbón, al petróleo y a los combustibles fósiles.

Power-to-X puede además resolver otro gran obstáculo para la transición energética: el almacenamiento. star thermal resuelve la cuestión de la sal licuada en regiones soleadas, pero no en latitudes alternativas.

En este momento, las turbinas eólicas en el norte de la RFA, por ejemplo, suelen producir la mayor parte de la energía que necesitan ser desconectadas de la red para evitar la sobrecarga.

En cambio, ese exceso de energía eólica bien puede estar acostumbrado a dividir el agua en número atómico 8 y elemento, a través de la electrólisis. No sólo se conservará y ahorrará el elemento, sino que también se acostumbrará a calentar edificios, construir acero o entrar en las celdas de combustible para maniobrar camiones y barcos.
Una vez que se tiene el elemento, de hecho, las probabilidades continúan. A través de un método que agrega la emisión de gases de efecto invernadero, usted producirá aceite de carbón artificial, gasolina o diesel. La "potencia líquida", porque se piensa, también puede ser usada para construir productos químicos variados.

La tecnología en sí no es nada nuevo: durante la Segunda Guerra Mundial, la RFA fabricó cantidades gigantescas de aceite de carbón artificial para su fuerza aérea. Ahora, mientras buscamos métodos para intentarlo sin usar combustibles fósiles, es un renacimiento y se diseñan otras plantas de demostración, principalmente en Europa.

El CO2 requerido para crear estos combustibles será filtrado de las emisiones de las centrales eléctricas de carbón, cemento o biogás, o aún más alto para un mundo sin emisiones de CO2, directamente del aire.

En 2017, la compañía nacional Climeworks inauguró una central eléctrica con ventiladores absorbentes Brobdingnagian que aspiran unas 900 toneladas métricas de CO2 del aire cada año. La empresa afirma que actualmente los precios son de 550 euros por unidad de peso métrico o CO2, aunque los consultores afirman que con la multiplicación de la demanda, los costes pueden caer a 50 euros por tonelada en 2050. Actualmente existen catorce plantas de este tipo en Europa, con un adicional en el método.

En este momento, los altos precios son probablemente la mayor barrera para que la energía se multiplique cada vez más para satisfacer nuestros deseos energéticos. La mayor parte de los elementos siguen estando fabricados a partir de combustibles fósiles y de combustibles fósiles, lo que resulta mucho más barato que obtenerlos a partir de energías alternativas.

Aún así, el arcángel Sterner, miembro de la facultad de economía política de la energía en la Universidad de Ciencias Aplicadas de Regensburg, dice que si los precios de los daños climáticos fueran tomados en consideración, "el hidrógeno se establecería rápidamente como otro.

Sterner podría ser un pionero de la tecnología y dice que hemos llegado a una etapa en la que los precios pueden empezar a caer. "Ahora nos proponemos entrar en la producción industrial".

Señala que hace veinte años, el fenómeno eléctrico de las estrellas (FV) todavía aparecía a un precio prohibitivo, sin embargo con el apoyo del Estado, la demanda se disparó, la tecnología mejoró y las economías de escala ayudaron a que los precios cayeran en picado.

# data[].attributes.attachment_link.title
Gracias al hidrógeno, la energía eólica y solar podrá reemplazar al combustible fósil y el petróleo - Ingeniero Químico Emprendedor: Ingeniería Industrial rama Química

# data[].attributes.attachment_link.description
Al convertir la energía eólica y solar en combustible, la energía-a-X puede liberar el transporte, la calefacción y los procesos industriales de los combustibles fósiles, una vez que los precios caigan. En todo el mundo se está generando más y más electricidad a partir de la energía eólica y solar.

# data[].attributes.attachment_link.provider_name
Ingeniero Químico Emprendedor: Ingeniería Industrial rama Química

# data[].attributes.attachment_link.title
Gracias al hidrógeno, la energía eólica y solar podrá reemplazar al combustible fósil y el petróleo - Ingeniero Químico Emprendedor: Ingeniería Industrial rama Química

# data[].attributes.attachment_link.description
Al convertir la energía eólica y solar en combustible, la energía-a-X puede liberar el transporte, la calefacción y los procesos industriales de los combustibles fósiles, una vez que los precios caigan. En todo el mundo se está generando más y más electricidad a partir de la energía eólica y solar. La tecnología ha avanzado enormemente […]

# data[].attributes.attachment_link.readable_text
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

Published today in Nature Biomedical Engineering, the University of Florida study showed that like a one-two punch, pairing the test vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response.

A surprising element, researchers said, was that they achieved the promising results not by attacking a specific target protein expressed in the tumor, but by simply revving up the immune system - spurring it to respond as if fighting a virus. They did this by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. The research was supported by multiple federal agencies and foundations, including the National Institutes of Health.

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, said the results reveal a potential new treatment path - an alternative to surgery, radiation and chemotherapy - with broad implications for battling many types of treatment-resistant tumors.

# data[].attributes.attachment_link.title
Surprising finding could pave way for universal cancer vaccine

# data[].attributes.attachment_link.description
An mRNA vaccine boosted the effectiveness of immune therapy for cancer in mice.

# data[].attributes.attachment_link.readable_text
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

Published today in Nature Biomedical Engineering, the University of Florida study showed that like a one-two punch, pairing the test vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response.

A surprising element, researchers said, was that they achieved the promising results not by attacking a specific target protein expressed in the tumor, but by simply revving up the immune system - spurring it to respond as if fighting a virus. They did this by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. The research was supported by multiple federal agencies and foundations, including the National Institutes of Health.

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, said the results reveal a potential new treatment path - an alternative to surgery, radiation and chemotherapy - with broad implications for battling many types of treatment-resistant tumors.

# data[].attributes.attachment_link.title
Surprising finding could pave way for universal cancer vaccine

# data[].attributes.attachment_link.description
An mRNA vaccine boosted the effectiveness of immune therapy for cancer in mice.

# data[].attributes.attachment_link.readable_text
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

Published today in Nature Biomedical Engineering, the University of Florida study showed that like a one-two punch, pairing the test vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response.

A surprising element, researchers said, was that they achieved the promising results not by attacking a specific target protein expressed in the tumor, but by simply revving up the immune system - spurring it to respond as if fighting a virus. They did this by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. The research was supported by multiple federal agencies and foundations, including the National Institutes of Health.

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, said the results reveal a potential new treatment path - an alternative to surgery, radiation and chemotherapy - with broad implications for battling many types of treatment-resistant tumors.

# data[].attributes.attachment_link.title
Surprising finding could pave way for universal cancer vaccine

# data[].attributes.attachment_link.description
An mRNA vaccine boosted the effectiveness of immune therapy for cancer in mice.

# data[].attributes.attachment_link.readable_text
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to "wake up" the immune system against cancer.

Published today in Nature Biomedical Engineering, the University of Florida study showed that like a one-two punch, pairing the test vaccine with common anticancer drugs called immune checkpoint inhibitors triggered a strong antitumor response.

A surprising element, researchers said, was that they achieved the promising results not by attacking a specific target protein expressed in the tumor, but by simply revving up the immune system - spurring it to respond as if fighting a virus. They did this by stimulating the expression of a protein called PD-L1 inside of tumors, making them more receptive to treatment. The research was supported by multiple federal agencies and foundations, including the National Institutes of Health.

Senior author Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, said the results reveal a potential new treatment path - an alternative to surgery, radiation and chemotherapy - with broad implications for battling many types of treatment-resistant tumors.

# data[].attributes.attachment_link.title
Surprising finding could pave way for universal cancer vaccine

# data[].attributes.attachment_link.description
An mRNA vaccine boosted the effectiveness of immune therapy for cancer in mice.

# data[].attributes.attachment_link.readable_text
Global Desk

In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology-the creators of the Sputnik V COVID-19 vaccine-announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months.

Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions.

A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early.

Q. What is mRNA, and how is it used in vaccines?
A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body.

This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites.

Gintsburg elaborated that the entire vaccine development cycle-from tumor sequencing to vaccine production-can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies.

Q. What is a personalized cancer vaccine?
A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines.

The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis.

The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers.

The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding.

According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program.

Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.

Add

# data[].attributes.attachment_link.title
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine

# data[].attributes.attachment_link.description
Russia's Gamaleya Center, famed for Sputnik V, will initiate human trials for a personalized mRNA melanoma vaccine by late 2025. This innovative vaccine, tailored to individual tumor genetics using AI, aims to stimulate the immune system to target and eradicate cancer cells.